Jazz Pharmaceuticals to Buy Gentium for $1B

Jazz Pharmaceuticals and Gentium S.p.A. Announce Agreement for Jazz Pharmaceuticals to Acquire Gentium for $57.00 Per Share Transaction would add a significant growth product in the European Union and Rest of World markets, Defitelio , a treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell ... (more)

http://www.drugs.com/news/jazz-pharmaceuticals-buy-gentium-1b-49695.html?